Observations, page-3

Thanks RBx - the potential of Veyonda in a suppository form is abundantly clear.

Can I ask then, based on that potential, why the company’s resources and efforts are not being solely or primarily dedicated to expediting a Phase 2 trial?

Would shareholders prefer

a) a company with a laser like focus on getting to a Phase 2 trial outcome (ie: DAART), and dedicating all of the majority of the company’s resources to that OR

b) a company which has multiple shots on goal, including multiple P1 combos, investigator initiated, and drug development at pre-clinical / earlier phases, but without a clear sense of direction around delivering a P2 outcome, and potentially losing time (and being overly stretched) on a number of fronts? Perhaps letting go of one or two things to focus on the main game?

Sorry I’m sounding inflammatory here, but I do think these options need to be tested.